3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Classical hematology
1
Conditions
Hematologic Neoplasms
1
Febrile Neutropenia
1
Interventions
fludarabine
10
Cyclophosphamide
8
fludarabine phosphate
7
Whole-Body Irradiation
7
Tacrolimus
5
Mycophenolic Acid
5
Melphalan
5
Thiotepa
4
Peripheral Blood Stem Cell Transplantation
4
Busulfan
4
AP 1903 reagent
4
thymoglobulin
3
Sirolimus
3
Cord Blood Stem Cell Transplantation
3
Alemtuzumab
3
Stem Cell Transplantation
2
Specimen Handling
2
Rituximab
2
Platelet Transfusion
2
Meropenem
2
Cyclosporine
2
Biopsy
2
Antilymphocyte Serum
2
visilizumab
1
venetoclax
1
trametinib
1
ruxolitinib
1
regorafenib
1
ponatinib
1
pertuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
ceftolozane, tazobactam drug combination
×
Classical hematology
×
Clear all
NCT05061654
2023-08-14
CEF-10
Hamad Medical Corporation
Phase 4
Withdrawn